[ad_1]
© Reuters. FILE PHOTO: The corporate’s brand is seen on the new cell and gene remedy manufacturing facility of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Picture
ZURICH (Reuters) – Novartis on Monday introduced the appointment of Gilbert Ghostine as chairman-designate of Sandoz, the generics unit Novartis needs to spin off later this 12 months.
Ghostine has been CEO of Geneva-based Firmenich, the world’s largest privately owned fragrance and style firm, since 2014.
He’ll turn out to be the chairman of the brand new board at Sandoz, which is to be shaped after its spin-off from Novartis within the second half of 2023, topic to closing Novartis Board of Administrators and shareholder approvals.
[ad_2]